Management of Hypertension in a 70-Year-Old Patient

Why the Elderly Deserve Special Attention

Blood Pressure Targets (2025 Current Guidance)

• HYVET trial (2008): Targeting < 150/80 mmHg in patients over 80 years reduced stroke by 30% and total mortality by 21% - the trial was stopped early due to clear benefit. First-line drug was indapamide (thiazide-like diuretic) ± perindopril (ACE inhibitor).
• SPRINT trial (2015): Targeting SBP < 120 mmHg in adults ≥75 years showed reduced CV events but a small increase in hypotension, syncope, and acute kidney injury.

Initial Assessment Before Starting Treatment

1. Confirm the diagnosis: Measure BP on ≥2 occasions, 2+ visits apart. Use home BP monitoring and ambulatory BP monitoring (ABPM) to exclude white-coat hypertension - common in the elderly.
2. Establish a baseline:
   • CBC, metabolic panel (electrolytes, creatinine, eGFR, glucose)
   • Fasting lipids, uric acid, urinalysis
   • ECG (screen for LVH, atrial fibrillation, ischemia)
3. Assess end-organ damage: LVH, CKD, retinopathy, PAD, prior stroke, CAD
4. Identify secondary causes: Renal artery stenosis is common in elderly (listen for abdominal bruit; think of it when BP is sudden-onset, rapidly worsening, or requires ≥3 drugs)
5. Screen for orthostatic hypotension: Measure BP standing after 1 and 3 minutes
6. Assess frailty, cognition, fall risk, and functional status

Step 1: Non-Pharmacological (Lifestyle) Management

Source: National Kidney Foundation Primer on Kidney Diseases, 8e; Swanson's Family Medicine Review

Step 2: Pharmacological Management

First-Line Drug Classes

Drug Selection by Comorbidity

Second-Line Options

• Cardioselective beta-blockers (metoprolol, bisoprolol, atenolol): Second-line in elderly unless there is specific indication (CAD, heart failure, post-MI, arrhythmia). Cause fewer side effects than non-selective beta-blockers.
• Spironolactone: Useful for resistant hypertension (4th drug).
• Reserpine (low dose with diuretic): Effective, especially in elderly, but rarely used today.

Drugs to Avoid in the Elderly

Combination Therapy

• Thiazide + ACEi or ARB (most common, ONTARGET-supported)
• Thiazide + CCB
• CCB + ACEi or ARB (ACCOMPLISH trial: superior to thiazide + ACEi for CV events)

Special Considerations in the 70-Year-Old

Orthostatic Hypotension

• Occurs in up to 20% of treated elderly hypertensives
• Check standing BP at each visit
• The 2025 AHA/ACC guideline notes improved BP control actually reduces CV risk without significantly increasing fall risk (SPRINT, CRHCP, NAILED trials) - but careful titration is still required

"Start Low, Go Slow" Principle

• Begin at half the usual adult dose
• Titrate upward gradually over weeks to months
• Target: bring SBP to 150 mmHg first, then aim for ≤130/80 over time

Frailty Assessment

• Frail or institutionalized patients (nursing home) may warrant a less aggressive target (140-150/90)
• In very frail patients, polypharmacy burden and quality of life considerations can outweigh tight BP control
• The 2023 systematic review on frail older adults (PMID 37594718) found guidelines lack uniform frailty-specific recommendations

Pseudohypertension

• Some elderly patients have falsely elevated cuff readings due to arterial calcification
• Suspect if: no end-organ damage despite high readings, or symptoms of hypotension despite "hypertensive" readings
• Osler's maneuver (palpable but pulseless radial artery with inflated cuff) suggests pseudohypertension

White-Coat Hypertension

• Particularly common in the elderly; prevalence up to 40%
• Use ABPM to confirm diagnosis before committing to lifelong therapy

Monitoring

• Electrolytes and creatinine within 2-4 weeks of starting ACEi/ARB or diuretics
• Potassium supplementation with thiazide diuretics (especially if K falls below 3.5 mEq/L)
• Renal artery stenosis: suspect if creatinine rises >30% after starting ACEi/ARB

Key Landmark Trials in Elderly Hypertension

Summary Algorithm for a Typical 70-Year-Old

BP ≥130/80 confirmed on ≥2 visits
        |
        ├── Lifestyle modifications (all patients, continue throughout)
        |
        ├── Assess comorbidities (DM, CKD, CAD, HF)
        |
        ├── No compelling indications:
        |     → Start thiazide diuretic (chlorthalidone 12.5-25 mg)
        |        OR amlodipine 2.5-5 mg
        |
        ├── Diabetes / CKD:
        |     → Start ACE inhibitor or ARB
        |
        ├── Not at target after 1-3 months:
        |     → Add second agent (CCB + ACEi, or thiazide + ACEi)
        |
        ├── Not at target on 2 agents:
        |     → Add third agent; consider specialist referral
        |        Exclude secondary causes (renal artery stenosis, primary aldosteronism)
        |
        └── Target: SBP <130/80 (most patients); <150/80 if frail/≥80 years

Recent Evidence Update (2024-2025)

• A 2024 Cochrane review (PMID 39688187) on higher BP targets in older adults found insufficient high-quality evidence to support routinely accepting higher targets, leaving the optimal goal uncertain in frail elderly.
• A 2025 Lancet IPD analysis (PMID 40902616) found intensive BP control (targeting <120 vs <140 mmHg) reduced composite CV and renal outcomes, but with trade-offs in adverse events - reinforcing the need to individualize.
• The 2025 AHA/ACC Guideline (published August 2025) reaffirms < 130/80 mmHg as the target for most adults including those over 65, with a class I recommendation that intensive BP control does not increase falls risk.